Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (TWST) announced it will acquire rights to a GPCR library and proprietary Twist Antibody Optimization software developed with Distributed Bio. This acquisition, initiated in 2016, enhances Twist's capabilities in antibody discovery using its silicon DNA synthesis platform. The GPCR library contributes to a 'Library of Libraries' with over 10 billion antibodies, facilitating optimized therapeutics. The financial terms remain undisclosed, and the move supports Twist's growth in synthetic biology and genomics, aiming to advance drug discovery and development.
AcornMed Biotechnology has announced a partnership with Twist Bioscience to integrate Twist's next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed's cancer precision medicine tests. This collaboration aims to enhance genetic analysis for better treatment strategies. Dr. Feng Lou, CTO of AcornMed, emphasized the importance of Twist's quality DNA synthesis in improving diagnostic accuracy. The partnership is expected to positively influence patient treatment and healthcare costs in China.
Twist Bioscience (NASDAQ: TWST) has partnered with Stanford University's Innovative Medicines Accelerator to provide access to its antibody discovery services and its innovative 'Library of Libraries.' This collaboration will enable Stanford researchers to utilize Twist’s advanced synthetic antibody libraries for various therapeutic targets. Twist will receive technology access fees and share in revenue from outlicensed antibodies. The first project aims to discover novel antibodies targeting a neuroscience application. The partnership showcases Twist's commitment to advancing biologics discovery through collaboration.
Twist Bioscience (TWST) has been awarded the Great Place to Work® Certification™, an accolade based on employee feedback regarding workplace culture and experience. This certification signifies Twist's commitment to fostering a positive work environment, even during challenges like the global pandemic. CEO Emily M. Leproust highlighted the importance of employees in driving growth and success. Twist offers competitive compensation, employee development, and robust family-friendly policies. The company specializes in synthetic DNA technology, impacting multiple sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has entered into a partnership with Kyowa Kirin Pharmaceutical Research, Inc. to discover novel antibodies targeting an undisclosed G protein-coupled receptor (GPCR). This collaboration utilizes Twist's unique 'Library of Libraries' for biologics discovery, enabling rapid antibody development. The partnership aims to enhance the efficiency and success rate of antibody therapeutics, leveraging Twist's scalable DNA manufacturing capabilities. An upfront payment was received, with Kyowa Kirin holding an option for development and commercial rights.
Twist Bioscience Corporation and Biotia have received Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This in vitro diagnostic test is designed to detect SARS-CoV-2 RNA with high sensitivity and analyze the entire viral RNA sequence, allowing for the identification of genetic variants. This assay is significant amid rising concerns over new viral mutations. The test enables batch processing of samples, enhancing public health responses against COVID-19. It is expected to be available for purchase soon.
Twist Bioscience Corporation (Nasdaq: TWST) announced positive preclinical data for GLP-1R antibodies from its proprietary GPCR libraries, showing effective blood glucose control. The data, published in mAbs, highlight 13 high-affinity GLP-1R antibodies that could have multiple clinical uses, including treatment for Type-2 diabetes. Notably, the antibody TB59-2 demonstrated a two-day half-life, indicating potential for once-weekly administration. CEO Emily M. Leproust emphasized collaboration with various partners to optimize antibody discovery.
Twist Bioscience Corporation (Nasdaq: TWST) has announced the shipment of new synthetic RNA reference controls for SARS-CoV-2 variants B.1.351 and P.1, as well as controls for the B.1.1.7 variant in a stabilized format. These products aim to enhance global surveillance efforts amid increasing vaccination rates. The company continues to provide essential tools to identify and monitor COVID-19 mutations, demonstrating commitment to public health. Twist's synthetic controls, based on specific SARS-CoV-2 variants, are designed to cover the full viral genome and are verified for accuracy.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Watchmaker Genomics to enhance research capabilities in high throughput sequencing applications. Their collaboration aims to facilitate innovations in oncology, inherited disease detection, and liquid biopsy assays. The first product will integrate Watchmaker's high-fidelity amplification technology into Twist's library preparation kits. Both companies focus on delivering exceptional products, optimizing workflows, and improving genomic studies quality through joint development initiatives.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
